EF Hutton Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Anavex Life Sciences (NASDAQ:AVXL) and maintained a price target of $46.
October 31, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton has reiterated a Buy rating for Anavex Life Sciences with a maintained price target of $46, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $46 price target by EF Hutton suggests a positive outlook for Anavex Life Sciences. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100